Skip to main content

Table 1 Characteristics of patients whose specimens were evaluated by immunohistochemistry

From: Myofibroblast expression in airways and alveoli is affected by smoking and COPD

 

Non-smokers (n=11)

Smokers with normal lung function (n=41)

Smokers with COPD GOLD stage I (n=6)

Smokers with COPD GOLD stage II (n=39)

Smokers with COPD GOLD stage III (n=4)

p-value

Age (y)

68 (7)

64 (8)

70 (9)

68 (8)

68 (10)

0.174

Sex m:f

2:9

29:12

5:1

37:2

4:0

 

Pack-years

0.6 (1.3)*

38 (15)

40 (14)

42 (14)

42 (12)

< 0.001

FEV1 (L) postbd

2.4 (0.7)

2.65 (0.73)

2.82 (0.26)

2.14 (0.40)

1.49 (0.17)¤

< 0.001

FEV1% pred

94 (18)#

82 (16)

91 (5)

64 (8)

43 (3)

< 0.001

FEV1/FVC

0.80 (0.08)$

0.79 (0.06)

0.67 (0.007)

0.59 (0.06)

0.54 (0.05)

< 0.001

DLCO (mmol/min/mmHg)

2.7 (2.1)

3.2 (2.5)

2.0 (1.9)

3.8 (2.4)

3.1 (2.7)

0.831

DLCO% pred

95 (17)*

73 (18)

65 (6)

66 (16)

67 (17)

< 0.001

  1. Mean (SD), *The mean difference between non-smokers and smokers is significant at the 0.05 level, Dunnett t-test, ¤The mean difference between non-smokers and smokers with COPD stage III is significant at the 0.05 level, Dunnett t-test, # The mean difference between non-smokers and non-obstructed smokers or smokers with COPD stage II or stage III is significant at the 0.05 level, Dunnett t-test, $The mean difference between non-smokers and smokers with COPD is significant at the 0.05 level, Dunnett t-test , GOLD Global Initiative for Chronic Obstructive Lung Disease, FEV 1 Forced expiratory volume in one second, FVC Forced vital capacity, DL co Diffusing capacity of carbon monoxide, postbd Post-bronchodilator value.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us